Literature DB >> 23430700

Provider impact on survival outcomes in the management of malignant disease.

Maurie Markman1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23430700     DOI： 10.1007/s11912-013-0304-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  18 in total

1.  Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants.

Authors:  Linda S Elting; Catherine Cooksley; B Nebiyou Bekele; Michael Frumovitz; Elenir B C Avritscher; Charlotte Sun; Diane C Bodurka
Journal:  Cancer       Date:  2006-06-01       Impact factor: 6.860

Review 2.  The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis.

Authors:  Michel W J M Wouters; Gea A Gooiker; Johanna W van Sandick; Rob A E M Tollenaar
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

3.  Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.

Authors:  Mohammad I Zia; Lillian L Siu; Greg R Pond; Eric X Chen
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

4.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Authors:  F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

Review 5.  Prognostic factors for survival in hepatocellular carcinoma.

Authors:  G Falkson; A Cnaan; A J Schutt; L M Ryan; H C Falkson
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

6.  Evaluation of patients with advanced cancer using the Karnofsky performance status.

Authors:  J W Yates; B Chalmer; F P McKegney
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

7.  Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients.

Authors:  C J Newschaffer; T L Bush; L E Penberthy; M Bellantoni; K Helzlsour; M Diener-West
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1998-09       Impact factor: 6.053

Review 8.  Paclitaxel (taxol)

Authors:  E K Rowinsky; R C Donehower
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

9.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

10.  Performance status score: do patients and their oncologists agree?

Authors:  S P Blagden; S C Charman; L D Sharples; L R A Magee; D Gilligan
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.